<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03227705</url>
  </required_header>
  <id_info>
    <org_study_id>13-159</org_study_id>
    <nct_id>NCT03227705</nct_id>
  </id_info>
  <brief_title>Canadian Study on the Association of Pessary With Progesterone</brief_title>
  <acronym>CAPP</acronym>
  <official_title>Canadian Study on the Association of Pessary With Progesterone</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Université de Sherbrooke</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Centre hospitalier de l'Université de Montréal (CHUM)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>CHU de Quebec-Universite Laval</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>St. Justine's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Jewish General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Ottawa Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Kingston Health Sciences Centre</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Université de Sherbrooke</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prematurity is the leading cause of neonatal morbidity causing more than 1 million deaths
      worldwide per year. In 2012, a randomized controlled trial (RCT) testing &quot;pessary&quot; (silicone
      ring placed around the cervix) versus &quot;no pessary&quot; in patients with a short cervix showed a
      4-fold reduction in the rate of spontaneous prematurity &lt;34 weeks of gestation and a
      reduction in perinatal morbidity and mortality. This result was not found in a subsequent RCT
      and another study on the subject had to be stopped in the face of slow recruitment.
      Currently, the obstetric scientific community believes that other RCTs are needed before
      using the pessary in the clinic as a therapeutic option to prevent prematurity in the
      presence of a short cervix. However, before starting a large RCT, it is important to test the
      feasibility of recruitment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hypothesis: A standardized recruitment process could allow the inclusion of 0.9% patient (CI
      95%: 0,78-1.04) among women receiving a 18-23 weeks ultrasound scan.

      Recruitment: Participants will be recruited, in a three-step manner, among women appointing
      for the 18-23 weeks ultrasound scan; i) assessment of the cervical length by abdominal
      ultrasound, ii) an endovaginal ultrasound measurement will be performed if the cervical
      length is ≤ 30 mm, iii) enrollment and consent of the patient to the pilot study, under the
      confirmation of the presence of a short cervix (≤ 25 mm) by the endovaginal ultrasound.

      Intervention: Vaginal progesterone (200 mg/day, PROMETRIUM®, Merck Canada Inc.) until 37
      weeks. Perforated cerclage pessaries (Dr. Arabin GmbH &amp; Co. KG) will be placed in specialized
      clinic and will be removed at 37 weeks.

      Size of the sampling and statistical analysis: This multicenter pilot study will be conducted
      in High-Risk Pregnancies Clinics in Quebec and in Ontario.

      Over the 12 months period, the investigators expect to collect data from 26 000 abdominal
      ultrasounds. In accordance with the anticipated recruitment level of 0.9%, the investigators
      planned on enrolling 250 women. Within those women, 125 will be assigned randomly to the
      &quot;progesterone&quot; group and 125 to the &quot;progesterone and pessary&quot; group (1:1 ratio).

      Perspective: This pilot study is designed to identify the challenges and provide strategies
      to deal with them in a larger study. Providing its feasibility, this study will lead to a
      definitive randomized controlled trial (including over 70 centers) to test the effectiveness
      of pessary and progesterone in preventing preterm birth.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 4, 2018</start_date>
  <completion_date type="Anticipated">October 2020</completion_date>
  <primary_completion_date type="Anticipated">April 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized, controlled clinical trial.</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Recruitment feasibility</measure>
    <time_frame>Up to 24 weeks (18 to 42 weeks of gestation)</time_frame>
    <description>According to the anticipated recruitment rate, 0.9% of women having an anatomy scan could be included (95% CI, 0.78- 1.04). We will determine the % of women included in the study (until the 42 week of gestation) over women that received a anatomy scan.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Preterm delivery</measure>
    <time_frame>Before 34 weeks</time_frame>
    <description>The secondary outcome is to determine the occurrence of spontaneous preterm births before 34 weeks in the progesterone alone group &quot; without pessary harm &quot;.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Preterm Birth</condition>
  <condition>Short Cervix</condition>
  <arm_group>
    <arm_group_label>Intravaginal progesterone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Once the participant agrees and signs the consent form, the use of prophylactic progesterone will begin (PROMETRIUM, 200 mg in total of progesterone, 2 vaginal capsules per day at bedtime up to 36 6/7 weeks of gestation, Merck Canada Inc.)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intravaginal progesterone and pessary</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Once the participant agrees and signs the consent form, the use of prophylactic progesterone will begin (PROMETRIUM, 200 mg in total of progesterone, 2 vaginal capsules per day at bedtime, Merck Canada Inc.). Also, a perforated pessary (Dr. Arabin, cerclage pessary perforated) will be inserted. The pessary will be removed and the progesterone treatment will be stopped at 36 6/7 weeks of gestation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prometrium</intervention_name>
    <description>Intravaginal use, off label, of Prometrium</description>
    <arm_group_label>Intravaginal progesterone</arm_group_label>
    <arm_group_label>Intravaginal progesterone and pessary</arm_group_label>
    <other_name>Progesterone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Dr. Arabin, cerclage pessary perforated</intervention_name>
    <description>A Dr. Arabin, cerclage pessary perforated will be inserted participants diagnosed with a short cervix</description>
    <arm_group_label>Intravaginal progesterone and pessary</arm_group_label>
    <other_name>Pessary</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patient with a short cervix equal to or less than 25 mm by transvaginal ultrasound

          -  gestational age between 18 (0/7) and 23 (6/7) weeks of gestation according to the
             results of the ultrasound of the first trimester, or by integrating the date of the
             last period

          -  patients who were informed of the study and agreed to sign the consent form.

        Exclusion Criteria:

          -  pregnancy with a fetus with a major congenital malformation - regular and painful
             uterine activity - history of preterm premature rupture of membranes (PPROM) - active
             vaginal bleeding - complete and incomplete placenta prævia - cerclage of the cervix in
             place - antecedent of conisation - multiple gestation - allergy/intolerance or
             hypersensitivity to progesterone or any of its ingredients.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>42 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean-Charles Pasquier, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Université de Sherbrooke</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marie-Belle Poirier, PhD</last_name>
    <phone>8193461110</phone>
    <phone_ext>12865</phone_ext>
    <email>marie-belle.poirier@usherbrooke.ca</email>
  </overall_contact>
  <location>
    <facility>
      <name>Kingston General Hospital</name>
      <address>
        <city>Kingston</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Heather Ramshaw</last_name>
      <phone>(613) 548-1372</phone>
      <email>ramshawh@queensu.ca</email>
    </contact>
    <investigator>
      <last_name>Graeme Smith, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Greg Davies, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ottawa Hospital</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H 8L6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Liz Davidson Grabiec, MSc</last_name>
      <phone>613-737-8899</phone>
      <phone_ext>77295</phone_ext>
      <email>edavidson@ohri.ca</email>
    </contact>
    <investigator>
      <last_name>Laura Gaudet, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sunnybrook Health Sciences Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>susan O'Rinn</last_name>
      <phone>416-480-6100</phone>
      <phone_ext>87716</phone_ext>
      <email>susan.orinn@sunnybrook.ca</email>
    </contact>
    <investigator>
      <last_name>Stefania Ronzoni, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jon Barrett, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre hospitalier de l'Université de Montréal</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <zip>H2X 0C1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sylvie Daigle</last_name>
      <phone>514 890-8000</phone>
      <phone_ext>36440</phone_ext>
      <email>sylvie.daigle.chum@ssss.gouv.qc.ca</email>
    </contact>
    <investigator>
      <last_name>Marie-Josée Bédard, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Sainte-Justine</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <zip>H3T 1C5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hasna Meddour</last_name>
      <phone>514 345-4931</phone>
      <phone_ext>7169</phone_ext>
      <email>hasna.meddour@recherche-ste-justine.qc.ca</email>
    </contact>
    <contact_backup>
      <last_name>Gloria Sanchez</last_name>
      <phone>514 345-4931</phone>
      <phone_ext>7580</phone_ext>
      <email>gloria.sanchez@recherche-ste-justine.qc.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Louise Duperron, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>François Audibert, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CIUSSS du Centre Ouest-de-l'Île-de Montréal</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <zip>H3T 1E2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>St.Mary's Hospital Center</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mitra Vaezi, MD</last_name>
      <email>mitra.vaezi@ladydavis.ca</email>
    </contact>
    <contact_backup>
      <last_name>Mitra</last_name>
    </contact_backup>
    <investigator>
      <last_name>Atanas Nedelchev, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Québec-Université Laval</name>
      <address>
        <city>Quebec city</city>
        <state>Quebec</state>
        <zip>G1V 4G2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Université de Sherbrooke</name>
      <address>
        <city>Sherbrooke</city>
        <state>Quebec</state>
        <zip>J1H 5N4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marie-Belle Poirier, PhD</last_name>
      <phone>8193461110</phone>
      <phone_ext>12865</phone_ext>
      <email>Marie-Belle.Poirier@Usherbrooke.ca</email>
    </contact>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <link>
    <url>http://capp.crc.chus.qc.ca/</url>
    <description>Clinical trial website</description>
  </link>
  <verification_date>October 2018</verification_date>
  <study_first_submitted>July 12, 2017</study_first_submitted>
  <study_first_submitted_qc>July 20, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 24, 2017</study_first_posted>
  <last_update_submitted>October 22, 2018</last_update_submitted>
  <last_update_submitted_qc>October 22, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">October 24, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Université de Sherbrooke</investigator_affiliation>
    <investigator_full_name>Jean-Charles Pasquier, MD, PhD</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <keyword>Preterm birth</keyword>
  <keyword>Short cervix</keyword>
  <keyword>Pessary</keyword>
  <keyword>Progesterone</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Premature Birth</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Progesterone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

